Last reviewed · How we verify
Acetaminophen and Diphenhydramine Only Product
At a glance
| Generic name | Acetaminophen and Diphenhydramine Only Product |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Upper Respiratory Tract Infection
- Lymphopenia
- PAIN IN EXTREMITY
- LEUKOCYTOSIS
- EDEMA LIMBS
- FALL
- HYPERTENSION
- Anaemia
- COGNITIVE DISTURBANCE
- DEPRESSION
- HEADACHE
Key clinical trials
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (PHASE3)
- Daratumumab in STK11 Mutated NSCLC (PHASE2)
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE2)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies (PHASE1)
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) (PHASE1, PHASE2)
- Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma (PHASE3)
- A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: